Grifols (GRFS) Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Grifols in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GRFS shares.
View GRFS analyst ratings or view top-rated stocks.

7 Wall Street research analysts have issued 1 year price objectives for Grifols' stock. Their GRFS share price forecasts range from $9.00 to $20.30. On average, they expect the company's stock price to reach $12.52 in the next twelve months. This suggests a possible upside of 42.3% from the stock's current price.
View analysts price targets for GRFS or view top-rated stocks among Wall Street analysts.

Grifols' stock was trading at $8.50 on January 1st, 2023. Since then, GRFS stock has increased by 3.5% and is now trading at $8.80.
View the best growth stocks for 2023 here.

Grifols, S.A. (NASDAQ:GRFS) released its quarterly earnings results on Tuesday, May, 4th. The biotechnology company reported $0.21 earnings per share for the quarter, missing the consensus estimate of $0.22 by $0.01. The biotechnology company earned $1.43 billion during the quarter.

ETFs with the largest weight of Grifols (NASDAQ:GRFS) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB),

Shares of Grifols split before market open on Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly issued shares were payable to shareholders after the closing bell on Thursday, December 31st 2015. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

205 employees have rated Grifols Chief Executive Officer Raimon Grifols and Victor Grifols Deu on Glassdoor.com. Raimon Grifols and Victor Grifols Deu has an approval rating of 68% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Grifols investors own include Gilead Sciences (GILD), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Abbott Laboratories (ABT), Alibaba Group (BABA), Johnson & Johnson (JNJ), NVIDIA (NVDA), AbbVie (ABBV), Bristol-Myers Squibb (BMY) and Nektar Therapeutics (NKTR).

Grifols trades on the NASDAQ under the ticker symbol "GRFS."

Grifols' stock is owned by many different institutional and retail investors. Top institutional shareholders include Brandes Investment Partners LP (1.50%), Black Creek Investment Management Inc. (1.09%), First Trust Advisors LP (0.81%), Pictet Asset Management SA (0.80%), FIL Ltd (0.67%) and Bank of America Corp DE (0.62%).

Shares of GRFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GRFS stock can currently be purchased for approximately $8.80.

Grifols (NASDAQ:GRFS) has a market capitalization of $6.05 billion and generates $6.39 billion in revenue each year.

The company employs 26,314 workers across the globe.

Grifols' mailing address is 152 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The official website for the company is www.grifols.com. The biotechnology company can be reached via phone at (493) 571-0221, via email at inversores@grifols.com, or via fax at 34-93-571-0267.